Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease

Experimental Gerontology

Volumn 95, Issue , 2017, Pages 39-43

  Kwon, Youngjoo ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Alzheimer's disease; Anti inflammatory agents; Inflammation; Luteolin

Indexed keywords

LUTEOLIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; NEUROPROTECTIVE AGENT;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; DRUG EFFECT; HUMAN; LIPID DIET; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DISEASE MODEL; IMMUNOLOGY; METABOLISM; OXIDATIVE STRESS;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION MEDIATORS; LUTEOLIN; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 85019852361     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2017.05.014     Document Type: Review

References (41)

1. Alzheimer's, A., 2014 Alzheimer's disease facts and figures. Alzheimers Dement. 10:2 (2014), e47–e92.
2. Alzheimer's Disease Anti-inflammatory Prevention Trial Research G, Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 9:6 (2013), 714–723.
3. Blennow, K., de Leon, M.J., Zetterberg, H., Alzheimer's disease. Lancet 368:9533 (2006), 387–403.
4. Breitner, J.C., Baker, L.D., Montine, T.J., Meinert, C.L., Lyketsos, C.G., Ashe, K.H., et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 7:4 (2011), 402–411.
5. Burton, M.D., Rytych, J.L., Amin, R., Johnson, R.W., Dietary luteolin reduces proinflammatory microglia in the brain of senescent mice. Rejuvenation Res. 19:4 (2016), 286–292.
6. Cagnin, A., Brooks, D.J., Kennedy, A.M., Gunn, R.N., Myers, R., Turkheimer, F.E., et al. In-vivo measurement of activated microglia in dementia. Lancet 358:9280 (2001), 461–467.
7. Caltagirone, C., Cisari, C., Schievano, C., Di Paola, R., Cordaro, M., Bruschetta, G., et al. Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl. Stroke. Res. 7:1 (2016), 54–69.
8. Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65:3 (1999), 664–670.
9. Castello, M.A., Jeppson, J.D., Soriano, S., Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. BMC Neurol., 14, 2014, 169.
10. Gottlieb, S., Head injury doubles the risk of Alzheimer's disease. Br. Med. J., 321(7269), 2000, 1100.
11. Group A-FR, Follow-up evaluation of cognitive function in the randomized Alzheimer's disease anti-inflammatory prevention trial and its follow-up study. Alzheimers Dement. 11:2 (2015), 216–225 (e1).
12. Guo, D.J., Li, F., Yu, P.H., Chan, S.W., Neuroprotective effects of luteolin against apoptosis induced by 6-hydroxydopamine on rat pheochromocytoma PC12 cells. Pharm. Biol. 51:2 (2013), 190–196.
13. Herrup, K., The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 18:6 (2015), 794–799.
14. Holmes, C., Review: systemic inflammation and Alzheimer's disease. Neuropathol. Appl. Neurobiol. 39:1 (2013), 51–68.
15. Imbimbo, B.P., Solfrizzi, V., Panza, F., Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. Front. Aging Neurosci., 2, 2010.
16. Jang, S., Kelley, K.W., Johnson, R.W., Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc. Natl. Acad. Sci. U. S. A. 105:21 (2008), 7534–7539.
17. Jang, S., Dilger, R.N., Johnson, R.W., Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J. Nutr. 140:10 (2010), 1892–1898.
18. Jayaraman, A., Pike, C.J., Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr. Diab. Rep., 14(4), 2014, 476.
19. Johnson, V.E., Stewart, W., Smith, D.H., Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease?. Nat. Rev. Neurosci. 11:5 (2010), 361–370.
20. Kotanidou, A., Xagorari, A., Bagli, E., Kitsanta, P., Fotsis, T., Papapetropoulos, A., et al. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am. J. Respir. Crit. Care Med. 165:6 (2002), 818–823.
21. Krstic, D., Madhusudan, A., Doehner, J., Vogel, P., Notter, T., Imhof, C., et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflammation, 9, 2012, 151.
22. Liu, Y., Tian, X., Gou, L., Sun, L., Ling, X., Yin, X., Luteolin attenuates diabetes-associated cognitive decline in rats. Brain Res. Bull. 94 (2013), 23–29.
23. Liu, Y., Fu, X.B., Lan, N., Li, S., Zhang, J.Z., Wang, S.S., et al. Luteolin protects against high fat diet-induced cognitive deficits in obesity mice. Behav. Brain Res. 267 (2014), 178–188.
24. Lopez-Lazaro, M., Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem. 9:1 (2009), 31–59.
25. Lyketsos, C.G., Grp, A.R., Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68:21 (2007), 1800–1808.
26. Murphy, M.P., LeVine, H. 3rd., Alzheimer's disease and the amyloid-beta peptide. Journal of Alzheimer's disease: JAD 19:1 (2010), 311–323.
27. Nguyen, J.T., Yamani, A., Kiso, Y., Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease: progress and problems. Curr. Pharm. Des. 12:33 (2006), 4295–4312.
28. Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., Ferri, C.P., The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement.: the Journal of the Alzheimer's Association 9:1 (2013), 63–75 (e2).
29. Rezai-Zadeh, K., Ehrhart, J., Bai, Y., Sanberg, P.R., Bickford, P., Tan, J., et al. Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J. Neuroinflammation, 5, 2008, 41.
30. Rezai-Zadeh, K., Shytle, R.D., Bai, Y., Tian, J., Hou, H.Y., Mori, T., et al. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J. Cell. Mol. Med. 13:3 (2009), 574–588.
31. Sawmiller, D., Li, S., Shahaduzzaman, M., Smith, A.J., Obregon, D., Giunta, B., et al. Luteolin reduces Alzheimer's disease pathologies induced by traumatic brain injury. Int. J. Mol. Sci. 15:1 (2014), 895–904.
32. Small, G.W., Siddarth, P., Silverman, D.H., Ercoli, L.M., Miller, K.J., Lavretsky, H., et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am. J. Geriatr. Psychiatry 16:12 (2008), 999–1009.
33. Thal, L.J., Ferris, S.H., Kirby, L., Block, G.A., Lines, C.R., Yuen, E., et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 30:6 (2005), 1204–1215.
34. Wang, J., Tan, L., Wang, H.F., Tan, C.C., Meng, X.F., Wang, C., et al. Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. J. Alzheimers Dis.: JAD 44:2 (2015), 385–396.
35. Wang, H., Wang, H., Cheng, H., Che, Z., Ameliorating effect of luteolin on memory impairment in an Alzheimer's disease model. Mol. Med. Rep. 13:5 (2016), 4215–4220.
36. Weaver, C.M., Bioactive foods and ingredients for health. Adv. Nutr. 5:3 (2014), 306S–311S.
37. Wu, W., Li, D., Zong, Y., Zhu, H., Pan, D., Xu, T., et al. Luteolin inhibits inflammatory responses via p38/MK2/TTP-mediated mRNA stability. Molecules 18:7 (2013), 8083–8094.
38. Xu, J., Wang, H., Lu, X., Ding, K., Zhang, L., He, J., et al. Posttraumatic administration of luteolin protects mice from traumatic brain injury: implication of autophagy and inflammation. Brain Res. 1582 (2014), 237–246.
39. Xu, J., Wang, H., Ding, K., Zhang, L., Wang, C., Li, T., et al. Luteolin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE pathway. Free Radic. Biol. Med. 71 (2014), 186–195.
40. Zhang, J.X., Xing, J.G., Wang, L.L., Jiang, H.L., Guo, S.L., Liu, R., Luteolin inhibits fibrillary beta-amyloid1–40-induced inflammation in a human blood-brain barrier model by suppressing the p38 MAPK-mediated NF-kappaB signaling pathways. Molecules, 22(3), 2017.
41. Zhu, L.H., Bi, W., Qi, R.B., Wang, H.D., Lu, D.X., Luteolin inhibits microglial inflammation and improves neuron survival against inflammation. Int. J. Neurosci. 121:6 (2011), 329–336.